论文部分内容阅读
目的探讨CA199、CA125、CEA和AFP联合检测在卵巢癌诊断中的应用价值。方法 2011年1月～2011年12月采用电化学发光法检测67例卵巢癌患者,57例卵巢良性肿瘤患者和52例健康对照者血清中CA199、CA125、CEA和AFP水平变化。结果卵巢癌组血清CA199、CA125、CEA和AFP水平均明显高于卵巢良性疾病组和健康对照组,差异有统计学意义(P﹤0.05)。卵巢良性疾病组血清CA199、CA125、CEA和AFP水平比较,差异无统计学意义(P﹥0.05)。CA199、CA125、CEA和AFP联合检测的敏感性明显高于CA199、CA125、CEA和AFP单独检测(P﹤0.05),但特异性比较差异无统计学意义(P﹥0.05)。结论 CA199、CA125、CEA和AFP联合检测能够提高卵巢癌的诊断率,有利于卵巢癌的早期发现。
Objective To investigate the value of combined detection of CA199, CA125, CEA and AFP in the diagnosis of ovarian cancer. Methods The serum levels of CA199, CA125, CEA and AFP in 67 patients with ovarian cancer, 57 patients with benign ovarian tumor and 52 healthy controls were detected by electrochemiluminescence method from January 2011 to December 2011. Results The levels of serum CA199, CA125, CEA and AFP in ovarian cancer group were significantly higher than those in benign ovarian disease group and healthy control group (P <0.05). There was no significant difference in serum levels of CA199, CA125, CEA and AFP between benign and malignant ovarian diseases (P> 0.05). The sensitivity of combined detection of CA199, CA125, CEA and AFP was significantly higher than that of CA199, CA125, CEA and AFP alone (P <0.05), but the difference was not statistically significant (P> 0.05). Conclusion The combined detection of CA199, CA125, CEA and AFP can improve the diagnosis rate of ovarian cancer and is beneficial to the early detection of ovarian cancer.